Orexo Announces Nomination Committee for Upcoming AGM
UPPSALA, Sweden – Orexo has officially appointed the members of its Nomination Committee ahead of the Annual General Meeting (AGM) scheduled for May 2025. This committee plays a vital role in shaping the future leadership and governance of the company.
Members of the Nomination Committee
The Nomination Committee is chaired by Henrik Kjaer Hansen, representing Novo Holdings A/S. Joining him on the committee are Claus Berner Møller from The Danish Labour Market Supplementary Pension, ATP, private investor Stefan Hansson, and James Noble, who serves as the Chairman of the Board of Orexo. This diverse group brings a wealth of experience and insight to the committee.
Key Responsibilities of the Nomination Committee
In preparation for the AGM, the Nomination Committee is tasked with proposing candidates for critical positions within the company. This includes nominations for the Chairman of the meeting, Chairman of the Board, and Board members, as well as recommendations on Board member fees and any remuneration for committee participation. They will also set forth principles for the composition of the committee itself.
Engagement with Shareholders
Orexo encourages shareholders who wish to contribute to the nomination process to submit proposals. They can contact the committee directly via email, ensuring that their voices are heard in shaping the governance of the company.
About Orexo
Orexo AB (publ.) is a prominent Swedish pharmaceutical company with nearly 30 years of expertise in developing advanced pharmaceutical formulations addressing significant medical needs. The company focuses on innovative treatment solutions, particularly for patients grappling with opioid use disorder in the US market. Orexo collaborates with leading partners around the globe to develop and commercialize products aimed at various therapeutic areas.
Financial Performance and Market Presence
In the previous fiscal year, Orexo reported total net sales of SEK 639 million, highlighting its strong market position and continued growth. With a dedicated workforce of 116 employees, Orexo stands listed on Nasdaq Stockholm’s main list and is also available as an American Depository Receipt on OTCQX under the ticker ORXOY in the United States, reflecting its commitment to accessibility and investor engagement.
Frequently Asked Questions
What is Orexo’s main business focus?
Orexo specializes in developing innovative pharmaceuticals, particularly for opioid use disorder and other critical medical needs.
Who leads Orexo’s Nomination Committee?
The committee is chaired by Henrik Kjaer Hansen, appointed by Novo Holdings A/S.
When is Orexo’s Annual General Meeting scheduled?
The AGM is set for May 8, 2025.
How can shareholders participate in the nomination process?
Shareholders can submit proposals via email to the Nomination Committee before the deadline.
Where can I find more information about Orexo?
For more details, visit Orexo’s official website and stay updated on their initiatives and product offerings.
